Thrombosis News and Research

Latest Thrombosis News and Research

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

Omega-3 fatty acids reduce risk of heart attack in stent patients

Omega-3 fatty acids, combined with two blood-thinning drugs, significantly changed the blood-clotting process and may reduce the risk of heart attacks in patients with stents in their heart arteries, according to research reported in Arteriosclerosis, Thrombosis and Vascular Biology: Journal of the American Heart Association.

27 May 2011

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

A pooled analysis of the global RESOLUTE clinical program presented today during a late-breaking clinical trials session at EuroPCR demonstrated the strong safety record of the Resolute drug-eluting stent (DES) from Medtronic, Inc., across a wide variety of patient and lesion types.

From Medtronic 21 May 2011

Blood stored in banks may undergo changes and damage

New research provides evidence for significant differences between new and old red blood cells used for transfusions and could provide a cheap, rapid and effective way to monitor the quality of blood supplies.

21 May 2011

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Six-month results from the BIOSOLVE-I first-in-man (FIM) trial, studying the DRug-Eluting Absorbable Metal Scaffold (DREAMS), demonstrate a high safety profile of the novel device.

19 May 2011

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

For patients with both heart disease and diabetes who took part in a pooled series of rigorous clinical trials, the Resolute drug-eluting stent from Medtronic, Inc., provided remarkably safe and effective outcomes, according to the results of several studies presented today at EuroPCR, a major international meeting for cardiac and vascular specialists.

From Medtronic 18 May 2011

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Elsevier announced the publication of an important position statement from the European Menopause and Andropause Society in the journal Maturitas on managing menopausal women with a personal or family history of venous thromboembolism.

18 May 2011

Accumetrics' VerifyNow P2Y12 Test receives CE mark approval for prognostic use

Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that the VerifyNow P2Y12 Test is now CE marked for prognostic use in identifying patients with high residual platelet reactivity on antiplatelet therapy who are at greater risk for future cardiovascular events.

17 May 2011

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Karo Bio AB is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications.

16 May 2011

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

ThromboGenics and co-development partner BioInvent International announce today that their partner Roche has dosed the first patient in a Phase Ib/II study with the novel antibody anti-cancer agent TB-403 (RG7334).

16 May 2011

Doctors miss blood clots costing millions to the NHS: Report

According to to figures from the NHS Litigation Authority, the NHS has paid out over £112m since 2005 in compensation because doctors have failed to spot or prevent fatal blood clots.

12 May 2011

Medtronic to present new clinical results on innovative medical devices at EuroPCR

New clinical data on a range of innovative medical devices from Medtronic, Inc., to treat cardiac and vascular diseases - from severe aortic stenosis and uncontrolled hypertension, to coronary and peripheral artery disease - will be presented next week at EuroPCR. Many of the presentations will be featured during late-breaking sessions at this large international interventional cardiology meeting, which takes place in Paris from May 17-20.

From Medtronic 12 May 2011

Study finds strong link between live birth rates and number of eggs retrieved in one IVF cycle

An analysis of over 400,000 IVF cycles in the UK has shown that doctors should aim to retrieve around 15 eggs from a woman's ovaries in a single cycle in order to have the best chance of achieving a live birth after assisted reproduction technology.

11 May 2011

Stenting is safe, effective and superior to balloon angioplasty for deep vein thrombosis treatment

Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis, according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions 2011 Scientific Sessions in Baltimore.

7 May 2011

Nation's emergency physicians warn about dangers linked with deep vein thrombosis

As temperatures warm and travel picks up around the country, the nation's emergency physicians issue a warning about the serious dangers associated with deep vein thrombosis.

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat life-threatening infectious diseases and acute cardiovascular disorders, announced that clinical data with PMX-60056 were presented at the American Heart Association's Arteriosclerosis, Thrombosis, and Vascular Biology Meeting in Chicago on April 28, 2011.

4 May 2011

Thoratec reports $99.5 million revenue for first quarter 2011

Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that revenues from continuing operations in the first quarter of fiscal 2011 were $99.5 million versus revenues of $99.3 million in the same period a year ago.

4 May 2011

Desirudin more effective for VTE prevention in patients with renal impairment

Desirudin reduced major venous thromboembolism and post-operative bleeding compared with the standard of care, enoxaparin, in patients with poor kidney function undergoing orthopedic surgery, according to a poster presented at the Arteriosclerosis, Thrombosis and Vascular Biology meeting.

3 May 2011

Thrombosis News and Research

Latest Thrombosis News and Research

Birth control pill safety issues raised

Omega-3 fatty acids reduce risk of heart attack in stent patients

Global clinical program demonstrates safety of Medtronic Resolute drug-eluting stent

Blood stored in banks may undergo changes and damage

Positive six-month results from BIOSOLVE-I FIM trial of DRug-Eluting Absorbable Metal Scaffold device

Clinical data of Medtronic's Resolute drug-eluting stent in diabetes presented at EuroPCR meeting

EMAS publishes position statement on women's post-reproductive health problems in Maturitas journal

Accumetrics' VerifyNow P2Y12 Test receives CE mark approval for prognostic use

Karo Bio symposium to discuss research on ER-beta and therapeutic applications

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Doctors miss blood clots costing millions to the NHS: Report

Medtronic to present new clinical results on innovative medical devices at EuroPCR

Study finds strong link between live birth rates and number of eggs retrieved in one IVF cycle

Stenting is safe, effective and superior to balloon angioplasty for deep vein thrombosis treatment

Nation's emergency physicians warn about dangers linked with deep vein thrombosis

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

PolyMedix Phase 1B/2 clinical study data presented at ATVB meeting

Thoratec reports $99.5 million revenue for first quarter 2011

Desirudin more effective for VTE prevention in patients with renal impairment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Thrombosis News and Research

Latest Thrombosis News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in